《吉瑞替尼克服FLT3野生型难治性/复发性急性髓系白血病患者对维奈克拉的原发性耐药：病例报告及可能机制探讨》勘误 [《Heliyon》第10卷，第16期，2024年8月30日，文章e35847]
Corrigendum to "Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms" [Heliyon Volume 10, Issue 16, August 30, 2024, Article e35847].
作者信息
Li Man, Yang Xiawan, Hong Yaonan, Liu Qi, Shen Yingying, Hu Tonglin, Shen Yiping, Kai Guoyin, Wu Dijiong
机构信息
Zhejiang Key TCM Laboratory for Chinese Resource Innovation and Transformation, Jinhua Academy, School of Pharmaceutical Sciences, The Third Affiliated Hospital, Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
出版信息
Heliyon. 2025 Feb 16;11(4):e42725. doi: 10.1016/j.heliyon.2025.e42725. eCollection 2025 Feb 28.
Abstract
[This corrects the article DOI: 10.1016/j.heliyon.2024.e35847.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.heliyon.2024.e35847。]
相似文献
1
Corrigendum to "Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms" [Heliyon Volume 10, Issue 16, August 30, 2024, Article e35847].《吉瑞替尼克服FLT3野生型难治性/复发性急性髓系白血病患者对维奈克拉的原发性耐药：病例报告及可能机制探讨》勘误 [《Heliyon》第10卷，第16期，2024年8月30日，文章e35847]
Heliyon. 2025 Feb 16;11(4):e42725. doi: 10.1016/j.heliyon.2025.e42725. eCollection 2025 Feb 28.
2
Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms.吉瑞替尼克服了一名FLT3野生型难治性/复发性急性髓系白血病患者对维奈托克的原发性耐药：病例报告及可能机制探索
Heliyon. 2024 Aug 10;10(16):e35847. doi: 10.1016/j.heliyon.2024.e35847. eCollection 2024 Aug 30.
3
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory -Mutated AML.阿扎胞苷、维奈托克和吉特替尼治疗新诊断和复发/难治性 - 突变 AML。
J Clin Oncol. 2024 May 1;42(13):1499-1508. doi: 10.1200/JCO.23.01911. Epub 2024 Jan 26.
4
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.维奈托克与吉特替尼联合应用通过抑制 MCL-1 在 FLT3 野生型高危急性髓系白血病中发挥协同作用。
Blood. 2022 Dec 15;140(24):2594-2610. doi: 10.1182/blood.2021014241.
5
Venetoclax Plus Gilteritinib for -Mutated Relapsed/Refractory Acute Myeloid Leukemia.维奈克拉联合吉特替尼治疗 - 突变的复发/难治性急性髓系白血病。
J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18.
6
Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine.两名对维奈克拉加阿扎胞苷无反应的FLT3-ITD突变急性髓系白血病患者对基于吉瑞替尼和维奈克拉的治疗产生快速有效反应
Onco Targets Ther. 2022 Feb 18;15:159-164. doi: 10.2147/OTT.S336715. eCollection 2022.
7
Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.吉特替尼与化疗用于治疗复发/难治性 - 突变型 AML。
N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.
8
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.吉特替尼联合或不联合维奈托克治疗复发/难治性 FLT3 突变型急性髓系白血病。
Br J Haematol. 2024 Sep;205(3):932-941. doi: 10.1111/bjh.19548. Epub 2024 May 23.
9
The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.欧洲药品管理局审查吉特替尼（Xospata）用于治疗伴有 FLT3 突变的复发性或难治性成人急性髓系白血病。
Oncologist. 2020 Jul;25(7):e1070-e1076. doi: 10.1634/theoncologist.2019-0976. Epub 2020 Mar 10.
10
The safety and efficacy of the re-administration of gilteritinib in a patient with FLT3-mutated R/R AML with CNS relapse: a case report.吉瑞替尼再次给药治疗伴有中枢神经系统复发的FLT3突变复发/难治性急性髓系白血病患者的安全性和有效性：一例病例报告
Front Oncol. 2024 Jul 2;14:1402970. doi: 10.3389/fonc.2024.1402970. eCollection 2024.
Zotero 插件